This long preclinical phase of AD could provide a critical opportunity for therapeutic intervention, given the development of novel immunotherapies that target and reduce the amount of Aβ and tau protein deposition in the brain, thereby slowing the disease process. The gene discussed is MAPT; the disease is Alzheimer disease.